Lancet Report

A team of researchers have found that some antiviral medications might have the potential to shorten symptoms and reduce the amount of time a patient is contagious with Monkeypox virus.

The scientists said more work is needed to reach any conclusions but their study found little evidence that another drug, brincidofovir, was beneficial

The research also reported the patient response to the first off-label use of two different antiviral medications -- brincidofovir and tecovirimat -- to treat the disease

According to Zydus, the plug-and-play technology of the vaccine equips it to adapt to the rapidly mutating SARS COV-2 virus.

The Lancet reported on Thursday that the country accounted for around 22.3 per cent of global excess deaths as of December 31, 2021

The study indicated that vaccines were 94 per cent effective at preventing hospitalisation 50-100 days after receiving the shot but fell to 80.4 per cent 200-250 days later

Overall, antibody levels were nearly 2.5 times higher against Omicron after three doses compared to after two jabs

A third 'booster' dose of Covid-19 vaccine successfully raises antibody levels that neutralise the Omicron variant, according to laboratory findings.

Experts say more real-world studies are required now

Extrapolating from the report, Lancet said 'two doses offer 77.8 per cent protection against symptomatic Covid-19'.

The study enrolled 621 participants, identified by the UK contact tracing system, between September 2020 and September 2021.

Researchers treated 739 randomly selected Brazilian COVID-19 patients with fluvoxamine, with another 733 receiving a placebo, between January 15 to August 6 of this year.

Digital technologies are transforming all areas of life and health, a trend that has been accelerated by the Covid-19 pandemic, but the benefits of these advances are not reaching everyone equally.

Vaccine efficacy against severe Covid-19 is so high, even for the Delta variant, that booster doses for the general population are "not appropriate" at this stage in the pandemic, a Lancet report said

Vaccine efficacy against severe Covid-19, even for delta variant, is so high that booster doses for the general population are not appropriate at this stage in pandemic, according to a Lancet review

Marginal increase in the number of people living with the ailment but diagnosis, treatment and control still need to catch up with best practices

The beneficial effects of COVID vaccines far outweigh the risk of facial paralysis on one side of the face known as Bell's Palsy, confirms a study published in The Lancet Infectious Diseases journal

Flu shot may protect against severe Covid effects, long-lasting Covid symptoms rare in children and other stories from around the country on the fight against the pandemic

Most children who develop COVID-19 symptoms recover after six days, and the number who experience symptoms beyond four weeks is low, according to a large UK study published in The Lancet Child & Adolescent Health journal. The study, based on data reported through a smartphone app by parents and carers, provides the first detailed description of COVID-19 illness in symptomatic school-aged children. "It is reassuring that the number of children experiencing long-lasting symptoms of COVID-19 symptoms is low. Nevertheless, a small number of children do experience long illness with COVID-19, and our study validates the experiences of these children and their families," said Professor Emma Duncan, lead author of the study, from King's College London, UK. The researchers noted that some adults experience a prolonged illness after COVID-19, described as long-COVID, where symptoms persist for four weeks or longer, but it is not known whether children can develop a similar condition or how .

The risk of heart attack and stroke is increased three-fold in the first two weeks following Covid-19, according to a study published in The Lancet journal.